Several other research firms have also recently weighed in on ILMN. BTIG Research assumed coverage on shares of Illumina in a research report on Friday, January 5th. They set a neutral rating on the stock. BidaskClub upgraded shares of Illumina from a hold rating to a buy rating in a research report on Friday, January 5th. William Blair cut shares of Illumina from an outperform rating to a market perform rating in a research report on Friday, January 5th. Evercore ISI assumed coverage on shares of Illumina in a research report on Wednesday, January 3rd. They set an outperform rating and a $250.00 price objective on the stock. Finally, Piper Jaffray Companies lifted their price objective on shares of Illumina to $274.00 and gave the stock an overweight rating in a research report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $220.13.
Illumina (NASDAQ ILMN) traded up $2.24 during midday trading on Tuesday, reaching $243.55. 894,788 shares of the company’s stock traded hands, compared to its average volume of 877,997. Illumina has a 12-month low of $156.50 and a 12-month high of $248.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The stock has a market cap of $35,890.00, a PE ratio of 45.95, a price-to-earnings-growth ratio of 3.24 and a beta of 0.79.
In related news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $210.43, for a total value of $4,208,600.00. Following the completion of the sale, the director now owns 539,176 shares of the company’s stock, valued at approximately $113,458,805.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction on Friday, December 1st. The shares were sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the sale, the director now directly owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. Insiders have sold a total of 154,671 shares of company stock valued at $33,626,228 in the last three months. Company insiders own 0.89% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in ILMN. Federated Investors Inc. PA lifted its stake in shares of Illumina by 46.2% in the 2nd quarter. Federated Investors Inc. PA now owns 3,704 shares of the life sciences company’s stock valued at $642,000 after purchasing an additional 1,171 shares during the last quarter. Neuberger Berman Group LLC lifted its stake in shares of Illumina by 35.7% in the 2nd quarter. Neuberger Berman Group LLC now owns 4,893 shares of the life sciences company’s stock valued at $849,000 after purchasing an additional 1,286 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at $226,000. Eaton Vance Management lifted its stake in shares of Illumina by 0.5% in the 2nd quarter. Eaton Vance Management now owns 15,927 shares of the life sciences company’s stock valued at $2,764,000 after purchasing an additional 84 shares during the last quarter. Finally, Riverhead Capital Management LLC lifted its stake in shares of Illumina by 20.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,313 shares of the life sciences company’s stock valued at $401,000 after purchasing an additional 397 shares during the last quarter. 91.60% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Given a $275.00 Price Target by Deutsche Bank Analysts” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2018/01/20/illumina-ilmn-given-a-275-00-price-target-by-deutsche-bank-analysts.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.